• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠道菌群失调是否会导致脆弱患者对严重急性呼吸综合征冠状病毒 2 产生异常炎症反应?

Does intestinal dysbiosis contribute to an aberrant inflammatory response to severe acute respiratory syndrome coronavirus 2 in frail patients?

机构信息

Department of Biomedical Sciences and Health, Università degli Studi di Milano, Milan, Italy; Department of Endocrinology, Nutrition and Metabolic Diseases, IRCCS MultiMedica, Milan, Italy.

Department of Biomedical Sciences and Health, Università degli Studi di Milano, Milan, Italy; Department of Endocrinology, Nutrition and Metabolic Diseases, IRCCS MultiMedica, Milan, Italy.

出版信息

Nutrition. 2020 Nov-Dec;79-80:110996. doi: 10.1016/j.nut.2020.110996. Epub 2020 Sep 1.

DOI:10.1016/j.nut.2020.110996
PMID:33002653
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7462523/
Abstract

In a few months, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become the main health problem worldwide. Epidemiologic studies revealed that populations have different vulnerabilities to SARS-CoV-2. Severe outcomes of the coronavirus disease 2019 (COVID-19) with an increased risk of death are observed in patients with metabolic syndrome, as well as diabetic and heart conditions (frail population). Excessive proinflammatory cytokine storm could be the main cause of increased vulnerability in this frail population. In patients with diabetes and/or heart disease, a low inflammatory state is often associated with gut dysbiosis. The increase amount of microbial metabolites (i.e., trimethylamine N-oxide and lipopolysaccharide), which generate an inflammatory microenvironment, is probably associated with an improved risk of severe illness from COVID-19. Nutritional interventions aimed at restoring the gut microbial balance could represent preventive strategies to protect the frail population from COVID-19. This narrative review presents the possible molecular mechanisms by which intestinal dysbiosis that enhances the inflammatory state could promote the spread of SARS-CoV-2 infection. Some nutritional strategies to counteract inflammation in frail patients are also analyzed.

摘要

在短短几个月内,严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染已成为全球主要的健康问题。流行病学研究表明,不同人群对 SARS-CoV-2 的易感性存在差异。患有代谢综合征、糖尿病和心脏病(脆弱人群)的患者,其 2019 年冠状病毒病(COVID-19)的严重后果及死亡风险增加。过度的促炎细胞因子风暴可能是该脆弱人群易感性增加的主要原因。在患有糖尿病和/或心脏病的患者中,低度炎症状态通常与肠道菌群失调有关。微生物代谢物(即三甲胺 N-氧化物和脂多糖)的增加量会产生炎症微环境,这可能与 COVID-19 重症风险的增加有关。旨在恢复肠道微生物平衡的营养干预措施可能代表预防策略,可以保护脆弱人群免受 COVID-19 的侵害。本综述介绍了肠道菌群失调增强炎症状态从而促进 SARS-CoV-2 感染传播的可能分子机制。还分析了一些针对脆弱患者的抗炎的营养策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d0c/7462523/eeba16326fee/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d0c/7462523/eeba16326fee/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d0c/7462523/eeba16326fee/gr1_lrg.jpg

相似文献

1
Does intestinal dysbiosis contribute to an aberrant inflammatory response to severe acute respiratory syndrome coronavirus 2 in frail patients?肠道菌群失调是否会导致脆弱患者对严重急性呼吸综合征冠状病毒 2 产生异常炎症反应?
Nutrition. 2020 Nov-Dec;79-80:110996. doi: 10.1016/j.nut.2020.110996. Epub 2020 Sep 1.
2
Microbiota Modulation of the Gut-Lung Axis in COVID-19.肠道菌群对 COVID-19 的肺肠轴的调节。
Front Immunol. 2021 Feb 24;12:635471. doi: 10.3389/fimmu.2021.635471. eCollection 2021.
3
Could Perturbation of Gut Microbiota Possibly Exacerbate the Severity of COVID-19 Cytokine Storm?肠道微生物群的扰动是否可能加剧 COVID-19 细胞因子风暴的严重程度?
Front Immunol. 2021 Jan 25;11:607734. doi: 10.3389/fimmu.2020.607734. eCollection 2020.
4
Tryptophan Metabolites and Aryl Hydrocarbon Receptor in Severe Acute Respiratory Syndrome, Coronavirus-2 (SARS-CoV-2) Pathophysiology.色氨酸代谢物和芳烃受体在严重急性呼吸综合征、冠状病毒-2 (SARS-CoV-2) 发病机制中的作用。
Int J Mol Sci. 2021 Feb 5;22(4):1597. doi: 10.3390/ijms22041597.
5
Coronavirus Disease (COVID-19) Caused by (SARS-CoV-2) Infections: A Real Challenge for Human Gut Microbiota.由(SARS-CoV-2)感染引起的冠状病毒病(COVID-19):人类肠道微生物组的真正挑战。
Front Cell Infect Microbiol. 2020 Dec 9;10:575559. doi: 10.3389/fcimb.2020.575559. eCollection 2020.
6
Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19.肠道微生物代谢物的改变可能介导了新冠病毒感染的危险因素的作用。
Rev Med Virol. 2021 Sep;31(5):1-13. doi: 10.1002/rmv.2211. Epub 2021 Jan 13.
7
Frailty and Adverse Outcomes After SARS-CoV-2 Infection in Elderly Patients on Maintenance Hemodialysis: A Cohort Study.在维持性血液透析的老年患者中,SARS-CoV-2 感染后的虚弱与不良结局:一项队列研究。
Clin Interv Aging. 2023 Nov 23;18:1937-1948. doi: 10.2147/CIA.S429226. eCollection 2023.
8
Autoimmunity and COVID-19 - The microbiotal connection.自身免疫与 COVID-19:微生物组的关联。
Autoimmun Rev. 2021 Aug;20(8):102865. doi: 10.1016/j.autrev.2021.102865. Epub 2021 Jun 10.
9
Gut Microbiota Dysbiosis Is a Crucial Player for the Poor Outcomes for COVID-19 in Elderly, Diabetic and Hypertensive Patients.肠道微生物群失调是导致老年、糖尿病和高血压患者新冠病毒疾病预后不良的关键因素。
Front Med (Lausanne). 2021 Aug 11;8:644751. doi: 10.3389/fmed.2021.644751. eCollection 2021.
10
Different aspects of frailty and COVID-19: points to consider in the current pandemic and future ones.衰弱的不同方面与 COVID-19:当前大流行及未来需考虑的要点。
BMC Geriatr. 2021 Jun 27;21(1):389. doi: 10.1186/s12877-021-02316-5.

引用本文的文献

1
The link between inflammatory/ SCFA profiles and oral/gut microbiome: an observational study in patients with ST-segment elevation myocardial infarction.炎症/SCFA谱与口腔/肠道微生物群之间的联系:一项针对ST段抬高型心肌梗死患者的观察性研究。
Curr Res Microb Sci. 2025 Jun 15;9:100423. doi: 10.1016/j.crmicr.2025.100423. eCollection 2025.
2
Decoding TMAO in the Gut-Organ Axis: From Biomarkers and Cell Death Mechanisms to Therapeutic Horizons.解读肠道-器官轴中的氧化三甲胺:从生物标志物、细胞死亡机制到治疗前景
Drug Des Devel Ther. 2025 Apr 29;19:3363-3393. doi: 10.2147/DDDT.S512207. eCollection 2025.
3
Metabolomic profiling of COVID-19 using serum and urine samples in intensive care and medical ward cohorts.

本文引用的文献

1
Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease.益生菌乳酸双歧杆菌V9减轻非酒精性脂肪性肝病大鼠的肝脏脂肪变性和炎症。
AMB Express. 2020 May 29;10(1):101. doi: 10.1186/s13568-020-01038-y.
2
Gut microbiota and Covid-19- possible link and implications.肠道微生物群与新冠病毒(COVID-19):可能的联系及影响。
Virus Res. 2020 Aug;285:198018. doi: 10.1016/j.virusres.2020.198018. Epub 2020 May 13.
3
Are probiotics effective adjuvant therapeutic choice in patients with COVID-19?
采用血清和尿液样本对重症监护和医疗病房队列中 COVID-19 的代谢组学分析。
Sci Rep. 2024 Oct 10;14(1):23713. doi: 10.1038/s41598-024-74641-9.
4
COVID-19 and Alzheimer's disease: Impact of lockdown and other restrictive measures during the COVID-19 pandemic.新型冠状病毒肺炎与阿尔茨海默病:新型冠状病毒肺炎大流行期间封锁及其他限制措施的影响
Biomol Biomed. 2024 Mar 11;24(2):219-229. doi: 10.17305/bb.2023.9680.
5
Stratification of hypertension and SARS-CoV-2 infection by quantitative NMR spectroscopy of human blood serum.通过人血清定量核磁共振波谱对高血压和SARS-CoV-2感染进行分层。
Commun Med (Lond). 2023 Oct 16;3(1):145. doi: 10.1038/s43856-023-00365-y.
6
Contribution of Trimethylamine N-Oxide (TMAO) to Chronic Inflammatory and Degenerative Diseases.氧化三甲胺(TMAO)对慢性炎症和退行性疾病的影响
Biomedicines. 2023 Feb 2;11(2):431. doi: 10.3390/biomedicines11020431.
7
SARS-CoV-2-associated gut microbiome alteration; A new contributor to colorectal cancer pathogenesis.SARS-CoV-2 相关的肠道微生物组改变;结直肠癌发病机制的新贡献者。
Pathol Res Pract. 2022 Nov;239:154131. doi: 10.1016/j.prp.2022.154131. Epub 2022 Sep 16.
8
Pre-Existing Microbiome Signature in a SARS-CoV-2 Discordant Family.一个新冠病毒检测结果不一致的家庭中的既有微生物组特征
Case Rep Gastroenterol. 2022 Feb 7;16(1):15-22. doi: 10.1159/000520625. eCollection 2022 Jan-Apr.
9
Association of gut-related metabolites with respiratory symptoms in COVID-19: A proof-of-concept study.肠道相关代谢物与 COVID-19 呼吸道症状的相关性:概念验证研究。
Nutrition. 2022 Apr;96:111585. doi: 10.1016/j.nut.2021.111585. Epub 2022 Jan 5.
10
High association of COVID-19 severity with poor gut health score in Lebanese patients.黎巴嫩患者的 COVID-19 严重程度与肠道健康评分差密切相关。
PLoS One. 2021 Oct 21;16(10):e0258913. doi: 10.1371/journal.pone.0258913. eCollection 2021.
益生菌对新冠病毒疾病患者而言是有效的辅助治疗选择吗?
Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4062-4063. doi: 10.26355/eurrev_202004_20977.
4
Angiotensin-converting enzyme-2 in SARS-CoV-2 infection: good or bad?严重急性呼吸综合征冠状病毒2感染中的血管紧张素转换酶2:是好是坏?
J Hypertens. 2020 Jun;38(6):1196-1197. doi: 10.1097/HJH.0000000000002472.
5
COVID-19: a new challenge for human beings.新冠病毒:人类面临的新挑战。
Cell Mol Immunol. 2020 May;17(5):555-557. doi: 10.1038/s41423-020-0407-x. Epub 2020 Mar 31.
6
Structural basis of receptor recognition by SARS-CoV-2.SARS-CoV-2 受体识别的结构基础。
Nature. 2020 May;581(7807):221-224. doi: 10.1038/s41586-020-2179-y. Epub 2020 Mar 30.
7
Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.血管紧张素转换酶 2 的器官保护作用及其对 COVID-19 预后的影响。
J Med Virol. 2020 Jul;92(7):726-730. doi: 10.1002/jmv.25785. Epub 2020 Apr 5.
8
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.肾素-血管紧张素系统阻滞剂与 COVID-19 大流行:目前尚无证据表明应放弃使用肾素-血管紧张素系统阻滞剂。
Hypertension. 2020 Jun;75(6):1382-1385. doi: 10.1161/HYPERTENSIONAHA.120.15082. Epub 2020 Mar 25.
9
Updated Approaches against SARS-CoV-2.更新的针对 SARS-CoV-2 的方法。
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.00483-20.
10
The positive impact of lockdown in Wuhan on containing the COVID-19 outbreak in China.封城对中国控制新冠肺炎疫情的积极影响。
J Travel Med. 2020 May 18;27(3). doi: 10.1093/jtm/taaa037.